Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Exclusion Criteria

• •1. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF (left ventricular shortening fraction)\<30% or LVEF(left ventricular ejection fraction)\<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart Association) III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment);
• •2. Has an active GvHD;
• •3. Has a history of severe pulmonary function damaging;
• •4. With other tumors which is/are in advanced malignant and has/have systemic metastasis;
• •5. Severe or persistent infection that cannot be effectively controlled;
• •6. Merging severe autoimmune diseases or immunodeficiency disease;
• •7. Patients with active hepatitis B or hepatitis C(\[HBVDNA+\]or \[HCVRNA
• •+\]);
• •8. Patients with HIV infection or syphilis infection;
• •9. Has a history of serious allergies on Biological products (including antibiotics);
• •10. Clinically significant viral infection or uncontrolled viral reactivation of EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BKvirus, or HHV(human herpesvirus)-6.
• •11. Presence of symptomatic disorders of the central nervous system, which include but not limited to uncontrolled epilepsy, cerebrovascular ischemia/hemorrhage, dementia, and cerebellar disease, etc.;
• •12. Have received transplant treatment for less than 6 months in prior to enrollment;
• •13. Being pregnant and lactating or having pregnancy within 12 months;
• •14. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study.